The Role of Tumor Microenvironment in Mycosis Fungoides and Sézary Syndrome

키워드

참고문헌 (72)

1. Willemze R, "The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas", Blood, 133, pp.1703~1714 (2019)
2. Jawed SI, "Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers", J Am Acad Dermatol, 70, pp.205~ (2014)
3. Sarantopoulos GP, "Mimics of cutaneous lymphoma: report of the 2011Society for Hematopathology", European Association for Haematopathology workshop, 2013, pp.139, 536~551
4. van Doorn R, "Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome", Blood, 113, pp.127~136 (2009)
5. McGirt LY, "Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides", Blood, 126, pp.508~519 (2015)
6. Choi J, "Genomic landscape of cutaneous T cell lymphoma", Nat Genet, 47, pp.1011~1019 (2015)
7. Bastidas Torres AN, "Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides", Genes Chromosomes Cancer, 57, pp.653~664 (2018)
8. van Kester MS, "miRNA expression profiling of mycosis fungoides", Mol Oncol, 5, pp.273~280 (2011)
9. Rubio Gonzalez B, "Tumor microenvironment in mycosis fungoides and Sézary syndrome", Curr Opin Oncol, 28, pp.88~96 (2016)
10. Wu XS, "Cutaneous T-cell lymphoma : roles for chemokines and chemokine receptors", J Invest Dermatol, 129, pp.1115~1119 (2009)
11. Fujii K, "New therapies and immunological findings in cutaneous Tcell lymphoma", Front Oncol, 8, pp.198~ (2018)
12. Lu D, "The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides", Am J Clin Pathol, 115, pp.413~421 (2001)
13. Nikoo A, "The expression of CXCR3 and CD30 in mycosis fungoides", Arch Iran Med, 15, pp.146~150 (2012)
14. Kuo PT, "The role of CXCR3 and its chemokine ligands in skin disease and cancer", Front Med(Lausanne), 5, pp.271~ (2018)
15. Sugaya M, "Chemokines and cutaneous lymphoma", J Dermatol Sci, 59, pp.81~85 (2010)
16. Sugaya M, "CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis", J Dermatol, 42, pp.613~615 (2015)
17. Yoshie O, "CCR4 and its ligands : from bench to bedside", Int Immunol, 27, pp.11~20 (2015)
18. Wu M, "Cutting edge : CCR4 mediates antigenprimed T cell binding to activated dendritic cells", J Immunol, 167, pp.4791~4795 (2001)
19. Jour G, "Differential expression of CCR4 in primary cutaneous gamma", delta(γ⁄δ)T cell lymphomas and mycosis fungoides : significance for diagnosis and therapy, 2018, pp.89, 88~91
20. Duvic M, "Phase 1", 2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous Tcell lymphoma, 2015, pp.125, 1883~1889
21. Ogura M, "Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma", J Clin Oncol, 32, pp.1157~1163 (2014)
22. Perera LP, "Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies", Am J Hematol, 92, pp.892~901 (2017)
23. Fierro MT, "Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sézary syndrome", Dermatology, 213, pp.284~292 (2006)
24. Notohamiprodjo M, "CCR10 is expressed in cutaneous T-cell lymphoma", Int J Cancer, 115, pp.641~647 (2005)
25. Fujita Y, "Presence of circulating CCR10+ T cells and elevated serum CTACK", CCL27 in the early stage of mycosis fungoides, 2006, pp.12, 2670~2675
26. Hughes CE, "A guide to chemokines and their receptors", FEBS J, 285, pp.2944~2971 (2018)
27. Murakami T, "Immune evasion by murine melanoma mediated through CC chemokine receptor-10", J Exp Med, 198, pp.1337~1347 (2003)
28. Sokolowska-Wojdylo M, "Circulating clonal CLA(+)and CD4(+)T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4and CCR10 as well as the lymph node-homing chemokine receptor CCR7", Br J Dermatol, 152, pp.258~264 (2005)
29. Picchio MC, "CXCL13 is highly produced by Sézary cells and enhances their migratory ability via a synergistic mechanism involving CCL19 and CCL21 chemokines", Cancer Res, 68, pp.7137~7146 (2008)
30. Daggett RN, "Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides", Br J Dermatol, 171, pp.722~731 (2014)
31. Ping YF, "The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cellmediated VEGF production and tumour angiogenesis via PI3K", AKT signalling, 2011, pp.224, 344~354
32. Miyagaki T, "Increased CCL18 expression in patients with cutaneous T-cell lymphoma : association with disease severity and prognosis", J Eur Acad Dermatol Venereol, 27, pp.e60~e67 (2013)
33. Saed G, "Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile", J Invest Dermatol, 103, pp.29~33 (1994)
34. Papadavid E, "The relevance of peripheral blood T-helper 1 and 2cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome", Br J Dermatol, 148, pp.709~718 (2003)
35. Vowels BR, "Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma", J Invest Dermatol, 103, pp.669~673 (1994)
36. Miyagaki T, "Immunological milieu in mycosis fungoides and Sézary syndrome", J Dermatol, 41, pp.11~18 (2014)
37. Hsi AC, "Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas : diagnostic implications", J Am Acad Dermatol, 72, pp.159~167 (2015)
38. Guenova E, "TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma", Clin Cancer Res, 19, pp.3755~3763 (2013)
39. Spaccarelli N, "The use of interferons in the treatment of cutaneous T-cell lymphoma", Dermatol Clin, 33, pp.731~745 (2015)
40. Urosevic M, "Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas", J Clin Invest, 117, pp.2834~2846 (2007)
41. Vieyra-Garcia P, "Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma", JCI Insight, 4, pp.e124233~ (2019)
42. Ghione P, "Novel immunotherapies for T cell lymphoma and leukemia", Curr Hematol Malig Rep, 13, pp.494~506 (2018)
43. Assaf C, "Mac attack : macrophages as key drivers of cutaneous T-cell lymphoma pathogenesis", Exp Dermatol, 25, pp.105~106 (2016)
44. Sugaya M, "Association of the numbers of CD163(+)cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma", J Dermatol Sci, 68, pp.45~51 (2012)
45. Furudate S, "The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides", Exp Dermatol, 25, pp.107~112 (2016)
46. Furudate S, "Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma", J Dermatol Sci, 83, pp.182~189 (2016)
47. Tanita K, "Bexarotene reduces production of CCL22 from tumor-associated macrophages in cutaneous T-cell lymphoma", Front Oncol, 9, pp.907~ (2019)
48. Kim YH, "Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level : a multi-institution collaborative project", J Clin Oncol, 33, pp.3750~3758 (2015)
49. Wu X, "Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo", J Invest Dermatol, 134, pp.2814~2822 (2014)
50. Wu X, "IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model", Leuk Lymphoma, 60, pp.1244~1252 (2019)
51. Russ A, "Blocking “don’t eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review", Blood Rev, 32, pp.480~489 (2018)
52. Folkes AS, "Targeting CD47 as a cancer therapeutic strategy : the cutaneous T-cell lymphoma experience", Curr Opin Oncol, 30, pp.332~337 (2018)
53. Nurmik M, "In search of definitions : cancer-associated fibroblasts and their markers", Int J Cancer, 146, pp.895~905 (2020)
54. Miyagaki T, "Low herpesvirus entry mediator(HVEM)expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma", J Invest Dermatol, 132, pp.1280~1289 (2012)
55. Murota H, "Periostin in the pathogenesis of skin diseases", Cell Mol Life Sci, 74, pp.4321~4328 (2017)
56. Takahashi N, "Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T-cell lymphoma", Cancer Res, 76, pp.6241~6252 (2016)
57. Miyagaki T, "Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma", J Invest Dermatol, 130, pp.2304~2311 (2010)
58. Berger CL, "The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells", Blood, 99, pp.2929~2939 (2002)
59. Schwingshackl P, "Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma : mycosis fungoides and Sézary syndrome", Acta Derm Venereol, 92, pp.269~275 (2012)
60. Ammendola M, "Mast cell-targeted strategies in cancer therapy", Transfus Med Hemother, 43, pp.109~113 (2016)
61. Rabenhorst A, "Mast cells play a protumorigenic role in primary cutaneous lymphoma", Blood, 120, pp.2042~2054 (2012)
62. Eder J, "Mast cells are abundant in primary cutaneous T-cell lymphomas : results from a computer-aided quantitative immunohistological study", PLoS One, 11, pp.e0163661~ (2016)
63. Geskin LJ, "Therapeutic reduction of cell-mediated immunosuppres-sion in mycosis fungoides and Sézary syndrome", Cancer Immunol Immunother, 67, pp.423~434 (2018)
64. Maliniemi P, "Biological and clinical significance of tryptophancatabolizing enzymes in cutaneous T-cell lymphomas", Oncoimmunology, 6, pp.e1273310~ (2017)
65. Querfeld C, "Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile", Cancer Immunol Res, 6, pp.900~909 (2018)
66. Kantekure K, "Expression patterns of the immunosuppressive proteins PD-1", CD279 and PD-L1, mycosis fungoides, pp.Am J Dermatopathol, 2012[DOI]
67. Samimi S, "Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma : implications for immune suppression", Arch Dermatol, 146, pp.1382~1388 (2010)
68. Gordon SR, "PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity", Nature, 545, pp.495~499 (2017)
69. Fujimura T, "Significance of immunosuppressive cells as a target for immunotherapies in melanoma and non-melanoma skin cancers", Biomolecules, 10, pp.1087~ (2020)
70. Leuchte K, "Innovative treatment concepts for cutaneous T-cell lymphoma based on microenvironment modulation", Oncol Res Treat, 40, pp.262~269 (2017)
71. Peranzoni E, "Improving efficacy of cancer immunotherapy through targeting of macrophages", Hum Vaccin Immunother, 15, pp.189~192 (2019)
72. Wu X, "A small molecule CCR2 antagonist depletes tumor macrophages and synergizes with anti-PD-1 in a murine model of cutaneous T-cell lymphoma(CTCL)", J Invest Dermatol, 140, pp.1390~1400 (2020)

관련 논문AI추천